title: Non-nucleoside analogue polymerase inhibitors in development.
abstract: Non-nucleoside polymerase inhibitors have several limitations including low to moderate potency, a low barrier to resistance, unlikely to cross genotype activity, genotype potency 1b > 1a, and hyperbilirubinemia for 2 of the drugs (tegobuvir and BI-207127). These drugs will have no role in monotherapy and may have only a limited role in triple therapy. They could be part of a quadruple therapy regimen or a triple or quadruple interferon-free regimen. Several issues remain unclear at the time of this review; the role of these compounds including minimal dosing required, safety, and cost remains to be clarified.
authors.affiliation: Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, CA 92037, USA. pockros.paul@scrippshealth.org
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Pockros
mesh_terms: D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D016174:Hepacivirus / Q000201:enzymology* / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans
chemical_list: D004791:Enzyme Inhibitors; D012321:DNA-Directed RNA Polymerases